Botul inuin toxin has several impo rtant properties that make it an ideal eheniiea l denervator. These include its high degree ofspecijicityfo r the neu roniuscularjunct ion, its ability to indu ce tempora ry and reve rsible denervation, and its limited degree ofside effects and complications. Botulinum toxi n is being usul safely in a wide variety of clinical settings by man y differen t spec ialists. In otolaryngologic practice, it is bei ng adminis tered fo r the treatmeilt of at least a dozen conditions, including various dysphonias, dysto nias, and spastns as weil as torticollis.fa cial nerve paralysis, and hyperkinetic f acial lines. Studies ha ve shown that botulinum tox in injections ha ve a high rate of success in tempo rarily relieving symptotns.
Introduction
Botulinum toxin is of interest to otolary ngologists for several reasons . First , it is becoming incr easingly popular as a treatment for several otolaryn gol ogic disorders, includin g spas modic dysph onia s, hemi faci al spasms, facial wrinkl es, and cricopharyngeal spas ms . Sec ond , alth ough its neur otoxic prop erties have been known for about 100 yea rs, it is only in the past IS yea rs 0 1' so that we have begun to understand its structure and mech ani sm of action.
Stiil , there is much we do not know abo ut this substance, and we are in the infancy phase of its use as a diagnostic and therapeutic age nt. On going research is helpin g to cIar ify some of the less we il understood biochem ical aspec ts of botul inum tox in, as we il as addressing the pro blems we face in using it as a chemical Reeovery from the neu rotoxin ' s effee ts is partl y mediated by the eell bod y' s ability to synthesize and transport material to the nerv e ending.' Two we ll-doe ume nted effeets of paralysis are the sprouting of new nerv e termi-naIs and an inerease in the number of postjunetional reeeptors . Exp erim ent al ev idenee in soleus and gastroenem ius mu sel es indi eat es that ne rve sprouts be gin to appea r approx imately 10 da ys after neuro museular blockade and that most nerve terminals dem on str ate sprouting after 3 weeks .v? At fir st, the spro uting is not funetio nal , although some spro uts do make eontaet ove r an area outsi de the neu romuseular juneti on and do beeome funetion al. Abno rmalities in the patt ern of reinnervation are not uniform and ean be prolon ged . Evid en ee also indiea tes th at the re is a n inerea se in th e number of postjuneti on al receptors.' :" Mu sel e atro phy oee urs during the initi al peri od of den er vation , stabilizes, and then dissipates over several mo nths, although mieroseopie abnarma lities might stiil be seen." Studies eonfirming the lon g-t erm miero seopi e ehanges in mu seles injeeted with botulinum toxin are laeking in humans.
Th ere are other reason s for the variability in treatment respon ses . Mu sele fibers ean be affeeted differentl y by the same dose oftoxin . Experimental evid enee sugg es ts that fast-tw iteh mu sele fibe rs remained fu neti onally den ervated lon ger than slow -tw iteh fibers .? Thi s is in eontrast to other ev ide nee that suggests that fas t-twitch fibers in the thyroarytenoid and lateral erieoarytenoid museles are reinnervated mare rapidly and to a grea ter degree than slow-twi teh fibers. ? Th e thyro ar yten oid and lateraI erieoarytenoid mu seles have a high propartion offast-twiteh fibers that are invo lve d in glottie sphineterie action and a low proportion of slow-twi teh fib er s that are invol ved in phonation . Th is migh t partiall y ex plain why the sid e effee ts of breathiness and aspiration follo wing botulinum toxin inj eeti on s are tran sien t whil e the reli ef fro m spas tici ty is lon g lastin g. Fin ally, we do not kno w what effeet mu sele aetiv ity has on the duration of musele paraly sis . W on g et al dem on str ate d that responses to botulinum toxin treatm ent for spas mod ie dysphonia were supe rior and lon ger lasting when pat ients und erwent a period of postinj eeti on voice rest. 10Th e relat ion ships bet ween botulinum toxin respon se and mu sel e type and aeti vit y are only now being eluei dated.
Th ere are also differene es in the durati on and de gree of respon se to botulinum toxin that eann ot be expl ai ned by the afore me ntioned observations . Som e patients who ha ve a good initi al respon se might need larger do se s over the durati on of treatm ent. Oth ers ex perience a redueti on in relief from spas m and a sho rter duration of response over tim e . On e possible ex plana tion fo r these dim ini shed respon ses might be the fo rma tion of antibodies to botulinum toxin. Howe ver , BigIan et al were unabl e to identify any antibody res po nse to sma ll do ses of botulinum toxin A. 11 Perh ap s larger doses-in the ran ge of 300 mou se 
Chronle Idioo athie Urticaria
Adverseevents reported by pati ents 12 years oI age and olderin plaeebo-eontrolledehronie idiopathic urtiearia studies were similar to those reported in plaeebo-controlled seasonal allergic rhinitis sludies. In plaeeboeontrolled ehronie idiopathic urtie aria clini cal trial s. which ineluded 726 patient s 12 years oI age and older r ; el~~b~~n~; ĩ~e~~~ĩ o" e~rodr \; h~~~d~~~~~~~r~~eods~~g:~. t a~~O 3ml~s~v~eJv~~i~'e~~~~r : ; e~~e~t s p~~; :~I ; i~c i~d~; , ; r i at~~t l r e~~i ĩy~~r~~r r~~~~~~~~~f t ; i uti~~f~Ot~PJ~: i~d s J i i r; da~~t~~~xa~i n:~~n f h~i~~;~I : : : b~c ommon with lexofenadine hydroehloride than placeba. The salely 01lexolenadine hydroehloride in the Ireal-ment01 ehronie idiopathie urtieari a in pediatrie palients 6 to 11 years oI age is basedon the salely profile oI lexotenadinehydroehlorideinadulls andadoleseent patients at doses equal to or higherIhan thereeommended dose (see Pediatric Use). 
Seasanal Alleroie Rhinitis
Adu lis. In placebo-controlled seasonal allergie rhinitis el iniealtrials in patients 12 years 01age andolder, whieh included 2461 panentsreeeiving lexolenadinehydroehloride capsules al doses 0120mgto 240mgtwicedaily. adverseevents wereslrnilar in fexofenadine hydrochloride and placebo-treated patients, All adverse eventsthat were report ed b Ö greater than 1% of patients wha received the recommended daily dose of fexofenadinẽ ra~~;~. Ĩ~ĩi i J~d~g T~~:~l es twice daily). and Ihat weremorecommonwi lh lexolenadine hydroehlorideIhan In a placebo-ccntrolled elinieal studyin theUnited states. which ineluded 570patlents aged 12 years and older reeeiving lexolenadine hydroehloridetablets al doses 01120 or180 mgonce daily. adverse events weresirnllar in lexolenadine hydroehlorideand plaeebo-treated patients. Table 1 • . .. . . . . . . . . . . . . . . . . . . . . . . . also lists adverse experiencesthat we rereported by greate r than2% 01palients treatedwith lexolenadine hydroehloridetablets at doses 01180mg once daily and that weremore common withlexolenadine hydroehloridethan plaeebo. The incidenee of adverse events. includi ng drowsiness. was not eese-reiateo and was similar aeross subgroups delined by age. genefer, and race. xetoconazoie (400 mgonce daily) The ehanges in plasmalevels werewithin the rangeoI plasma levels aehieved ,nadequateand well -eontrolledcliniea l trials. The meehanism al these interaetions has beenevaluated in in vitro. in situ. and in vivo anirnal modets. These studies indieale that ketoeanazoieor erythromyein eo·admini strationenhanees fexofena· dinegaslrointestinal absorption_In vivo animal sludies alsosuggest that in addition to inereasi ng absorption, ketoeonazole decreases lexol enadine hydroehl oride gaslroinlestinal secretion. while eryl hromyein mayalsodeereasebiliary exeretion. Orug InteraetiDns wilh Anl aeids Adminislration01120 mgof lexolenadine hydroehloride (2 x 60 mg eapsule) \'Ii thin 15 minutes of an aluminum and magnesi um containing anlaei d (Maalo" ) deereased lexolenadine AUC by 41% and C max by 43%. ALLEGRAshould noI betaken el osely in timewilh aluminumand magnesiumcontaining antaeids.
.
Carelnogenesls Mutagenesls Impalrment ofFertility
Thecarcinogenie potenti al and reproductivelo, ieily oI lexolenadine hydroehlaride Vlereassessed using tertenadine studieswith adequate lexolenadine hydroehlorideexposure (based onplasmaarea-under -Ihe-eonee ntralionvs. time [AUC)values). No evidenee 01earcinogeni eily was observedin an 18-month sludy in miceand in a24-monlh studyIn rats at aral doses up to 150 mglkg ot terfenadine(whiehledto lexolenadine exposures that e i : x~~~~i~\: Ĩ y1r~~~1b~~~e:~da u1~s~~~m~; i I 1h r~; r pos u r e Iromthe maximum reeommendeddail y oral dose
In in vitro (Baeteri al Reverse Mulation. CHOIHGPRT Forward Mut ati on. and Rat Lymphoeyte Chromosomal Aberration assays) and in vivo (Mouse Bone Marrow Mieronuel eus assay) tests. lexofenadine hydroe hloride revealed no evidenee ofmut agenieity .
In rat lertilily sludies. dose-rel ated reduetions in impl ants and iner eases in postimplantation losses were observedal an oral dose of 150 mglkg 01terlenadine (which led to lexolenadine hydrochloride exposures that : d;o~g Fo' r~~~~~tĩU l r S) t i mes the exposure 01 the ma,imum reeommended dail y aral dose oI lexolenadinẽ Teralo genieElfeels: Cal egoryC. There was no evidence oI leratogenieily in rals or rabbits at oral doses 01 terlenadine up to 300 mg/kg (which ledto lexolenadine exposures that were approximalely 4 and 31 times. respeetively. Ihe expos urelrom the maximum reeommended daily oraldose 01lexolenadi ne in adul ls)_ There are no adequale and weil eontrolled studies in pregnanl women. Fexolenadi ne should be used during pregnaneyonly il Ihe potenli al benelil justilies the pot ential risk to Ihe tetus. Nonl eralogenft Elfeels. Oose-rel aled decreases in pup Vleighl gain andsurvival Vle reobserved in rals exposed 10 an oraldoseoI 150 mglkg 01lerlenadine(approximatel y 3 times themaximum recommendeddaily oral dose 01lexolenadine hydroehloridein adults based on comparison oI lexolenadine hydroehlorideAUCs 
Avenlis Phormaceuticols
Parsippany, Nl 07054 NEUENSC HWANDER, PRIBITKIN, SATALO FF un its (MU) dur ing a 30 -day period-mi ght lead to an antibody res po nse . Th e total cu mulative dose might also be a fac tor in antibo dy produ ction . Fin all y, so me drugs (e.g. , aminoglycoside antib iotics) ca n poten tiate and prolon g the effec t of botul inu m tox in, whereas others (e.g., gua nidi ne and ami no pyridines) can limit its effect .' Th e roles of anti bo dy for mation and dru g po tentiation have not been pro ven ei ther clin ically OI' in the lab orator y, and they remai n incompletel y understood .
Types of preparations
Th ere are two comme rc ially avai lable form s of bo tulinum toxin : Botox and Dysp ort. Botox is supplie d in the Un ited States by All erg an (l rvine, Cali f.). A new batch prepared in 1998 co ntains less albumin than the original batch , whi ch was prepared in 1979. Botox is packaged in vial s of 100 MU . Dysport is supp lied by Speywood (W rex ha m, W ales). It is packaged in vials of 500 MU. Th e two fo rmulations are not equivale nt. Furtherm or e, either brand ' s poten cy can va ry amo ng the indi vidu al vials in eac h package, whic h mu st be kep t in mind whe n reading the literatu re and treating pat ients. T he dose req uired to kill 50 % of a batch of mice is I MU . T he lethal dose for hum ans has been ex trapolate d fro m mo nkey ex pe rime nts and is thought to be 2,500 to 3,000 MU, which is we il above the commo n doses used in otolaryngology (usua lly 1.25 to 75 M U).
Th e toxin is mark eted in a Iyoph ilized for m, which must be diluted with normal saline to ob tai n the desired con centrati on . For example, a lOO-MU vial that is dilu ted with 2 mi of saline yields 5 MU/O.I mI. Different co nce ntration s and different vo lumes are used fo r vario us purposes. For example, becau se the co nce ntratio ns are different , a sma ller vo lume can be used for inj ectin g 10 MU into a thy roaryten oid mu scle than for injec ting 10 MU into the orbicularis oculi.
Th e FDA rec ommend s that the toxin be used within 4 ho urs of reconstitution, and it suggests that refreezi ng leads to a loss of acti vit y. Al110 ng the valid co nce rns abo ut stor ing toxin fo r later use are the alteration of its moleculal' structure, the development of antibo dies, incon sisten t respo nses , and irreg ular dosing patterns .':' E ven so, one study of forearm injecti on s showed that there was no difference in paral ysis between patients who had rece ived fresh toxin an d th ose who received toxin that had been refrozen OI' refrigerated for 2 weeks."
Uses in otolaryngology
Botulinum toxin is bein g administered for the treat ment of at least a do ze n co ndi tions in otolary ngo log ic practice. Among them are two types of spasmodic dysph oni a, add uctor lar yn geal breathing dyston ia, blepharospas m, hemifacial spasm, oro ma ndibular dys tonia, tort icoll is, facial nerv e paresis with synki nes is, hyperkineti c facial lines, and cricopharyngeal spas rn.
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Spasmodic dysphonias
Spasmodic dy spho nia is pro ba bly the mos t we ll-k now n use for bot ulin um tox in in otolary ngo logy. M uch work in this area has bee n done by Bli tzer and Brin,14.15 Woodson and colleagues," :" Ford and colleagues. P:" and Ludl ow and colleagues." Spasmodic dy sphon ia is be lieve d to be a di sorder of ce ntral motor processing. It is a foca l dys ton ia, and it is classified as one of two main types. Th e more co mmon adductor type is cha racterize d by involuntary spasms of the thyro arytenoid and other adductor mu scles, which ca use a strai ned OI' stra ng led vo ice . Th e abd uctor type is cha rac ter ized by int ermittent hy perabduction of the vocal fold s, wh ich gives the pati ent a breathy, whispe ry voic e . Althou gh speech therapy might be help ful and sho uld be atternpted, most non invasiv e therapi es are ine ffecti ve in co ntro lling sy mptoms .
A co rrec t diagn osis is essential in the mana gement of patients with lar yn geal dyston ias. Spasmodi c dysphoni a mu st be differentia ted fro m other neurologic disord er s that ca use vo ice dysfunction." :" An inco rrec t diagnosis ca n result in treat me nt wit ho ut effect, worsening sy mptoms, OI' even life-threaten ing co mp lica tio ns. Moreover, tre atme nt of a misdi agn osed pat ient wit h psychogenic dysphonia migh t res ult in a place bo effect that co uld incorrect ly support the inaccurate di agn osis and delay proper treatmen t.
Adductor spasmodic dysphonia. Injecti on of botul inum toxi n into the thyroar yten oid mu scle has been used since 1984 to treat adduc tor spas mod ic dyspho nia, and it is co nsidered the treatm ent of cho ice . lnj ection s ca n be ad ministered percutan eou sly or perorall y. Most autho rities-including Sataloff," Blit zer and Bri n, 15 Wo od son ,17 and Adamsv-s-use the percu tan eou s technique. A holIow , Tefl on-co ated , 27 -gau ge e lec tro myogra ph ic (E M G) needi e is used to pen etrat e the crico thyro id membrane. Th e needie is then directed superiorly and later all y tow ard the thyroaryten oid mu scl e, and the lar yn geal lum en is avo ide d. Con firm at ion that the prop er position has been reac hed occ urs whe n EMG shows a sha rp increase in electrical ac tiv ity as the patient phonates. Th e disa dv antage of this technique is that it requires an E MG machin e and a person who is fa miliar wi th the performance and interpretat ion of laryngeal EMG. ü ther au thors prefer the perorai technique. " :" Becau se motor endplates are tho ught to be distributed thro ughout the muscle, the pro ponents of pero rai injections argue that thi s technique allows them to mo re ea si ly diffuse toxin over the enti re muscle." Prior to injection , the larynx is anes thetized topi ca lly an d vis ualized by indi rec t laryngoscopy or flex ib le nasol aryn goscopy. A syringe fitted to a curve d lar yn geal inj ection needIe is used to deliver botul inum tox in to two sites thr ough the superior surface of the tru e vocal folds. Th is technique yields a high rate of success, and patients tolerate it we il. Fur thermore, Ford suggests th at the perorai approach requi res sma ller doses than the percutaneous techn ique beeau se loeali zation is more prec ise, although this idea is controversial. " :" Th e peroral approaeh also has the advantage of being a teehniqu e with whieh otolaryngologists are already familiar. Finally, it does not require EMG guidanee . Its disadv antages are the need for speeial needle s, the gre ater amount of time needed to deli ver the toxin , the need for an assistant , and the waste oftoxin that oeeurs beeause some of it remains unused in the catheter."
The size of the dose varies among patients and physician s. Blitzer and Brin first began injeeting 2.5 MU unil aterall y in patients with adduetor spas modie dy sphonia, but they eventually eame to believe that this amount had little effect." Onee they began injeeting an additional 7.5 MU , they noted the onset of vocal fold paresis and prolonged breathine ss and a 90% improvernent in funetion. They also attained sueeessful result s with bilateral injeetions of3 .75 MU . Blit zer and Brin have sinee modified their technique and now start with 1.25 MU bilaterally and titrate the dose upward until optimal funetion is aehieved. They note that eompl ete paralysis is not requir ed to ach ieve a good outeome. We have reported similar findin gs."
One of the most useful aspeets ofbotulinum toxin is that it ean be titrated to achieve the best possibl e result in eaeh individual. Doses ean range from as low as 1.25 MU to as high as 30 MU , depending on the respon se, degree of side effects, and technique. Larger doses ean lead to greater improvement in vocal funetion but, of course, they are also associated with a greater degre e of side effeets. George et al reported that dose-related responses were seen with dos es up to 7.5 MU, and eomplete paraly sis was aehieved with JO MU .2 4They eoncluded thatdoses smaller than 10 MU are suffiei ent for elin ieal paraly sis.
In gen eral, pat ient s with adduetor spas modie dysphonia who reeeive botulinum toxin for the first time should be given a low do se-approximately 1.25 to 2.5 MU bilaterally or JO to 20 MU unilat erally. They should be followed up within 2 weeks, and the dos e should be adju sted as needed. Pat ients with a paralyzed vocal fold and those who have undergone a nerv e see tion might also benefit from low-dose inj ectio ns, aIthough their improvement might not be as dramatie. Clinieally, result s vary among patients, and treatment pattern s must be individ ualized . Result s also vary from treatment to treatment in the same patient.
Injeetions ean be administered unilat er ally or bilaterally in pati ents with adduetor spas modie dysphonia, although there is some eontrove rsy over the effie aey and degree of side effeets with the two techniques.t-P-> " Neverthele ss, both teehniques result in signifieant improv ements in voic e quality and normall y eau se onl y minim al and transient side effeet s. The mo st common side effeets are a shor t period, usuall y I to 2 weeks , of breathiness or hypophonia, dy sph agia, chokin g, pain at 794 the injeetion site, and edema of the vocal fold s iftoo mueh volume is injeeted. Exeessive weakness or more severe side effee ts ean oeeur ifthe toxin spreads to other adduetor mu scl es, such as the lateraI cricoarytenoid." No signifieant OI' long-term side effeets have been reported. Mieroseopie ehanges in motor unit s and a prolonged disorganization of motor unit s have been deseribed, and the process of reinnervation ean take as long as 3 years." Longer followup studies are needed to understand the long -terrn effeets of botulinum toxin.
Bilateral injeetions are usuall y administered beeause weakening OI' paraly zing only one vocal fold theoretieally stress es the other fold and ean exaggerate dystonie symptorns ." AIso, bilate ral injeetions expose the patient to less botulinum toxin beeause they ean be given in a smaller eumulative dose than unilateraI injeetions.
Respon ses ean be minimal OI' quite dramatie. Studies have shown that success rates are high .1 5.1 6.21 .22.28 It has been postul ated that by paralyzing the laryngeal muscle s and pos sibly altering a feedbaek loop , botulinum tox in might mod ify the inappropriate timing of phonatory mu scle s in the speeeh-motor loop ,16.29but the signifiea nee of this action has not been fully studied. Although botulinum toxin therapy might not always result in normal speech, it is a safe and reasonable treatment to restore flueney . Its effeet usually beeomes evident in 24 to 72 hours; maximum effeetiveness is seen in about 2 weeks, and it lasts on average 3 to 6 months, oeeasionally longer. Some patient s have gone into remis sion. The rea sons for this are not elear, but such instanees raise que stion s about the aeeuraey of the diagnosis.
Abductor spasmodic dysphonia. For patients with abduetor spasmodie dy sphonia, injeetions are delivered to the posterior erieoarytenoid muscle, although erieothyroid inj eetions have also been used. " :" These injeetions usually requ ire EMG guidanee. When one is injeeting the posterior er ieoarytenoid musele , the larynx is rotated away from the side of the injeetion and the needIe is plaeed pereut aneou sly int o the skin over the lateraI aspeet of the thyroid ala below its midpoint. EMG eonfirm ation ean be aehieved by having the patient sniff. The posterior erieoarytenoid mu scle ean also be reaehed through the erieothyroid membrane, espeeially in females and some youn g men. PeroraI injeetions ean also be performed; the erieothyroid is approaehed through the midline in a lateraI and superfieia I direction. Confirmation of proper needIe position is obtained by having the patient sing an aseending seale OI' slide (gli ssando) and observing an inerease in EMG aetivity as the piteh increases.
The posterior erieoarytenoid is injeeted with an initial do se of 3.75 MU, and this amount ean be titrated as nec essary ." If sy mptoms per sist and the posterior erieoarytenoid has already been eompletely paralyzed , the eont ralater al post erior erieoarytenoid ean be injeeted eautiou sly with very small inerements oftoxin. However, the NEUENS CH WANDER, PRIBITKIN, SATALO FF pati ent mu st be wi lling to aece pt the risk of airway co mpro mise. In pati ent s who fail th is technique, injection s into the cricothyroid ca n be performed.P'" Blit zer et al studie d 32 pati ent s with abductor spasmodic dysph on ia and found that after subjective pre-and postoperativ e evaluatio ns by pat ients, phy sicians, and speec h path ologi sts, the patient s' pereent age of normal functio n imp roved on ave rage from 31 to 70 %.31 Most of these patient s received bilateral posteri or cricoarytenoid inje cti on s. Th e autho rs did not co mme nt on the duration of res po nse. In ano the r study, Ludlow et al treat ed 10 patient s who had abduc tor spas mo dic dysph on ia and crico thyroid hyp eractiv ity.30Th ey fo und that six of the 10 patient s responded to cricothyroid inje ctions and ex perience d an increase in se ntence durati on (the len gth of tim e a patient is abl e to speak witho ut br eaks 0 1'breath s) and in their proportion of voiced speech. Patients returned fo r re injection at 4-to 6-month inter val s.
As is the case with pat ient s wh o ha ve adductor spasmodi c dysphonia, results in patients with abducto r spasmodic dysph oni a va ry, but man y do obtain ben efit from botul inum toxin inj ecti on s. Th e most worri sorne adverse effects see n with posterior cricoarytenoid injection s, especially bilateral inj ection s, are stri do r an d airway co mpromise, but they are not co mmo n. Wh en stridor does occ ur, it usu ally man ifests during ex ertion. Tw o othe r fai rly co mm on side effects are tran sient dy sph agia and as piration of fluids .
Special laryngeal applications
Botulinum toxin has been used by one of the authors (RTS.) and by others -Andrew Blitzer , MD (ora l co mmuni cati on , 1996 ), Mich ael Ront al , MD (oral communication, 1997 ), and Stev en Zeit eis, MD (oral communication , I998)-for a var iety of speci al laryngeal probiem s. Th e toxin ca n be used for the treatm ent of rec urre nt laryngeal granulornata, as an adj unctive tre atment for arytenoid disloc ati on , and for the man agem ent of laryngea l synki nes is assoc iated with reinnervati on afte r recu rrent ne rve par alysis. We ha ve also con sid ered its use in selected cas es of bilat eral vocal fo ld paraly sis.
Adductor laryngeaI breathing dystonia
Th e trea tment of adductor lar yngeal breath ing dystoni a (res piratory dystoni a) with botulinum toxin was described by Gr illon e et al in 1994 . 32 This co ndition is ch aracteri zed by a paradoxical adduction of the vocal fo lds during inspi ration , whi ch leads to stridor, Th e stridor usuall y disapp ears during slee p and worsens with exertio n. Th e vo ice is norm a!. M an y patient s ex perience a resp irat ory dysrh ythm ia, and many complain of severe fatig ue that ca n interfere w ith wo rk. Th ese pat ients ca n be treated with botulinum toxin inj ections into ea ch thyroa ryt enoid mu scle, usuall y with up to 3.75 MU, dep ending on the severi ty of the co ndition. Tr eatm ent ca n significa ntly 796 alle viate strido r and fa tig ue for up to 3 OI'4 months. Th e mo st co mmo n co mplications are a tran sien t breath y vo ice and a mild as piratio n of liqu ids.
Blepharospasm
Blepharospasm is a di sabling condition that ca n cause functi on al blindness. It invol ves the invo luntary activ ity ofthe orbiculari s oculi, proc erus, and co rrug ator supe rcilii mu scles. Its sy mpto ms inelude lower facial spas ms and or omandibular spas ms . Bleph arosp asm can oc cur in isolati on or as part of oth er condition s, suc h as Mei ge ' s sy ndrome .
Botulinum toxin ha s been used to successfully treat blepharospasm since 1982, and it is now the treatment of choice.v" Th e inje ctions can be give n with OI' wi tho ut EMG guidance . Without EMG guida nce, injection sites are determined by palp atin g the affected mu sel e groups. A 30-gau ge needie is used to inje ct sma ll doses at several sites laterally, medi ally, and infe riorl y. Pa tient s who do not res po nd might be nefit from bro w injection s. Inj ection s deli vered outside the orb ital rim have the sho rtes t duration of action and the least effec t, but they also cause the fewe st side effects.v" Initial doses range from 2.5 to 5.0 MU per site and are titr ated up ward to 12.5 to 30 MU per eye. Effect s are seen in 2 OI' 3 day s and ge nerally last 3 or 4 months.
Regardl ess of technique, the central part of the upp er eyelid sho uld not be inje cted in order to avoid pa ralysis of th e levato r palpebrae supe rio ris an d subsequent pto sis. Diplopia ca n occ ur if the toxin enters the ex traocular mu sel es. Other side effects inelude epiphora, oc ular irri tatio n, lagophthalm os, and ex pos ure ke ratitis. On rare occas ions, ec tropion, entro pion, or blurred visio n OCCUl'. 33.35.3638 Side effe cts can occur as a res ult of the diffu sion of toxin , but they can be minimized by inj ecting sma ller vo lumes and avoi di ng ma ssage of the region.
Hemifacial spasm
Hemifacial spas m usu all y begin s in the orbicularis oculi , and it ca n spread to invol ve the mu sel es of the bm w, lower face, and neck. Pati ents with hemi facial spas m (like those with blepharo spasm ) might have an underlyin g neu rologic di sord er or other condition that is cau sin g the ir spas m. For ex ample, hemifaci al spas m ca n be ca use d by a vascular loop compre ssion of the faci al nerve, or it might be associated with pa rkinso nis m 0 1' an other neurologic disord er characterize d by involuntar y mu sele spas ms. Regardl ess of the etiology, botulinum toxin provid es temporary reli ef of sy mpto ms .
Before con sidering botulinum toxi n the rapy, it is neeess ary to con duc t a co mplete evalua tion, which ca n inelude magnetic reson ance imaging, EMG , angiography, neurolo gic co nsultation, se lected bl ood tests, and other studies . lnj ection s ca n be guided by EM G, bu t many experienced physicians fee l co mfortable witho ut it. Patient s us ua lly receive 12 to 30 MU distributed in 2 .Sto S.O-M U doses . T he toxin is typicaIly injec ted into the zygomaticus major and mino r, the levator anguli oris, and the risorius. Im provem en t has been reported to occ ur in 92 to 100 % of patients." :" :" Th e dura tion of sy mp to m reli ef ex tends beyond 4 mon ths on average, bu t some pa tie nts require a rei njection after 10 weeks, some times sooner. A few patients have go ne into rernission." Over time, some patients requ ire larger doses, so me can ge t by with sma ller doses , and some are maintained on the same doses. Th e rea so ns for th is variability are not know n.
Side effects incl ude those see n wi th blepharospasm . Substantia l faci al we ak ness is noted occasiona lly. Facial asy mmetry, drooling, and chew ing problem s ca n also OCCUr. 33.35.36 .38But fo r man y pat ie nts, these side effects are incon sequential whe n cornpared with the disabl ing spasms of their disease.
To rt ico llis
Botul inum toxin has been used to trea t torticolli s ca use d by sternocleidomastoid spas m. Large doses are usuall y nee ded, sometimes 100 to 300 MU per sternocleido mastoid muscle. Local co mplicatio ns incl ude dysph agia and neck weakness, and systemic co mplica tio ns include pruritus, nau sea, flu-like symptoms , fatig ue, genera lized weakness, and dista nt, un related muscle weakness.t -P Dysphagia is tho ugh t to be caused by toxin diffusion into the constrictor mu scles. T oxin diffusion has been shown to be dose-re la ted. Th e toxin can spread ove r a la rge area and even cross fasc ial plane s. Sympto m re lief lasts II weeks on ave rage." Th e ph ysician sho uld kee p in mind concerns over the lon g-t erm effects of such large doses, particularly the risk ofdeveloping anti bodies aga inst botu linum toxin . Th ese doses are also high eno ugh to
Oromandibular dystonia
Orornand ibul ar dystoni a ca n occ ur alo ne or with other foca l or ge neralized dyston ias. Sp asm s of the mu scl es of masticati on ca n lead to pain , abnor ma l jaw positio ning, temporamand ibul ar j oint dysfunctio n, and trismu s. Th e d iagn osis ca n be difficult. In addition to botu linu m toxi n, treatrnents includ e anticholinerg ics and be nzodiazepines."
Botulinum toxin injec tions are delivered to those mu scles that appea r to be th e most spas modic , usu aIl y the te mpo ralis, masseter, an d med ial and lateral pter ygoids. lnjection s into the pt erygoids must be ma de wit h EMG guida nce. Toxin is delivered in one or more inj ection s of 10 MU distributed over the muscle . Doses range fro m 10 to 40 MU and can be titrated as necessary.40 Th e effects of botulinum toxin in oromandibular dystonia are see n in 24 to 72 hours and ge neraIly last 10 weeks to 4 months.' ? Patient s show significa nt imp ra vem ent and are able to ret urn to norm al ea ting and speaking hab its wi tho ut pai n.
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INOICATIONS AND USAGE
CIPRO' HCOTICsuspension is indieatedfor the treatment 01aeuteotitis externain adult and pediatrie patients, oneyear and older, due to suseeptiblestrains of Pseudomonas aeruginosa, Staphyloeoeeus aureus, and Proteus mirabilis. CONTRAINOICATIONS CIPRO' HC OTICIs eontraindieatedin persons with a hi story 01 hype rsensitivity to hydroeortisone, ei profloxaein or any member 01 the quinolone class 01ant imierobia l agents. Thi s nonsteriie produetshould not beused il the tympanie membrane is perlorated. Use 01 this produetiscontralndlcated in viral intectlons of theexternal eanal ineludingvariee llaand herpes simplex inleetions. RatHepatoeyte DNA Repair Assay MieronueleusTest (Miee) Dominant LethalTest (Miee) Long-term earei nogenieity studies in miee and rats have been eompleted for eiprofloxaein. Allerdaily oral doses 01 750 mg/kg (rnlce)and250 mg/kg (rats) wereadministered for up to 2 years, therewas noevidenee thateiprofloxaein had anyeareinogenie or tumorigenie etteets in these specles. No long term studies 01CIPRO' HC OTICsuspension have been pertormed to evaluate eareinogenie potential. Fert ility studiespertorrnec in rats at oral doses 01eiprolloxaein up to 100 mglkg/dayreveal ed no evidenee 01impairment. This would beover1000 times the maximum reeommended elinieal dose of ototopieal eiprolloxaein based upon body surtace area, assumingtotal absorption 01ei prof loxaein Irom the ear01a patient treatedwith CIPRO' HCOTICtwice perday. Long term studieshave notbeen performed to evaluate the carcinoqenic potential ortheelfeet on fertili ty 01topieal hydroeortisone.Mutagenieitystudieswith hydroeortisonewere negative. Pregnaney: Teratogenie Elfeets. Pregnaney Category C: Reproduction studies have beenpertormed in rats andmiee using oral doses of upto 100 mglkg and IVdoses upto 30 mglkg andhave revealed no evidenee 01har m to the letus asa resu lt 01 eiprofloxaein. Inrabbits, eiprofloxaein (30 and 100 mglkg orally)produeed gastrointestinal dist urbanees resulting in maternai weight loss andaninereased inei denee of abortion, but no teratogenieitywas observedatei therdose. Allerintravenous administration 01doses upto20mglkg, no ma ternai toxiei ty was produeed in the rabb it, and no embryotoxieity or teratogenieity was observed, Cortieosteroidsare generallyteratogenie in laboratory animaiswhen administered systemieally at relativel y lowdosage levels. The more potent eortieosteroi dshave been shown to beteratogenie aller dermai applieation in laboratory animals, Animal reproductionstudies have not beeneondueted wi thCIPRO' HCOTIC. Noadequate andweil eontrolled studies have been performed in pregnant women. Caution shouldbe exereised when CI PRO' HC OTICis usedbya pregnant woman. Nursing Mothers: Ciprolloxaein is exereted in human milk with systemie use. It is notknown whet hereiprofloxaein is exereted in human milk lollowing topieal otie administration. Beeause of thepotential for serious adverse reaetions in nursing infants, a declslon should be made whether to diseontinue nursing or to diseontinue fhedrug, takinginto aeeount theimportanee of the drug to the mother. Pedialrle use: The satety and elfieaey 01CIPRO' HC OTIChave been established in pediatr ie patients 2 years and older (131 patients) in adequate and wel l-eontrolled elinieal trials. Although no data areavailableonpat ients less thanage 2years, thereare no known satety coneerns or dillerenees in thedisease process inthis populat ion whieh would pree lude use 01 this produet in patients one year and older. See DOSAGE AND ADMINISTRATION. 
WARNINGS
AOVERSE REACTlONS
Hyperkinetic facial lines
Botulinum toxin has been helpful in treatin g the aging face . Glabell ar line s, cro w' s feet, deep forehead lines, and deep nasolabial fold s have all been treated success fully. Hyperkineti c line s are a res ult of pull on the skin by underlyin g muscles.Th e procerus and corrugator superci lii create deep lines in the glabe lla durin g frow ning. Crow' s fee t are created by the latera l orbicular is oc uli duri ng sq uinting. In the forehea d, lines are made by the frontalis muscle. Na solabial folds are created by the zygo maticus minor, levator labi i superior is, orbicularis oris , and levator lab ii superioris alaeq ue nasi. Carru thers et al first noted that pat ients who were treated for bleph arospasm, hemifacial spas m, and Bell' s palsy all displaye d a loss of wrinkles." Since then , botulinum toxin has been used to lessen or eliminate the degree of hyp er functional lines of the f ace . 6 . 9 EMG ca n be used to guide the placement of the needIe in the treatment of glabella r lines, but once a ph ysician becom es familiar with the technique, EMG can be dispen sed with . As is the case in the treatm ent of other types Facial nerve paralysis Th e management of patients with facia l nerve paresis can be very difficult. Invol unt ary eye lid elo sure and other facia l movements associated with fac ial nerve paralysis ca n be disfiguring. Th ese sig ns are associated wit h an aberrant rege neratio n of the facial ner ve. Amo ng the other treatm ent s for facial ner ve paralysis are ptosis repa ir, selec tive myectomy, and se lective neurectom y. But these procedures have their dra wba cks, includ ing the wea kening of an already den er vated muscle, their irreve rsibility, and the difficulty enc ountered in achieving optimal re-suIts.
Borodic et al studied 12 patient s with synkinesis followin g facial nerve paralysis who receiv ed a mean dose of 22 MU of botul inum toxin and found that improvem ent lasted abo ut 5 month s." Th e authors noted sig nificant improveme nt in sy nkinetic movement s, but per iocul ar injec tio ns increase d facial dyssymm etry. Minimizing the dose ca n limit diffu sion .
Pat ient s with facial nerve paralysis often do not regain co mplete functio n. Techniques to reanim ate the face often improve fac ial sy mme try, but they fail to do anything about the pull of the nor mal co ntralatera l face , which ca n be very defor min g. In these patien ts, botuli num toxin ca n be inj ected into the co ntralateral zygo maticus maj or and the risorius to impro ve symmetry at the nasolabial fold and ora l co mmiss ure. For patients with facia l nerv e paralysis, the uses of bo tulinum toxin in reh abilitation , surgica l reanim ation , and temp orary relief of spas m, synkines is, and asymm etry are evo lving ." Volume 79, Number 10 799 NEUEN SCH W ANDER , PRIBITKIN , SATALO FF of mu scle spas ms, the adva ntage of usin g EMG is that if a pati ent does not respond to the initial inj ec tio n, speci fic sites of persistent act ivit y can be ide ntified and subseq ue nt inje cti on s ca n be mad e wi th grea ter precision . If there is an abse nce o f activi ty, injection s ca n be placed in the orbicularis oc uli, corrugator supercilii, and front ali s mu scle s. It is imp ortant to rem ember that the injecti on s mu st be pla ced int o the lill/sel es, not the wrink les . Tr eatment usuall y begin s with 10 MU into each co rruga tor supe rcilii and ca n be repeated as necessary." Crow 's feet are treated in a si milar fashio n, usu all y with EMG guidance. Sm all er doses (5 MU) are used to treat eac h eye. Foreh ead lines and nasolabi al folds are treat ed with various amo unts of bo tulinum toxin. In each region , treatm ent ca n render a graded weake ning of the underl ying muscul ature an d a parti al or co mplete resoluti on of the hyp er kineti c lin es. When treatin g these areas, sma ll doses are del ivered to se ve ral sites . Results can be see n in 5 to 7 days, and the treatment effects last from 2 to 6 months.v" Pati ent s are ge nera lly sa tis fied wi th their outco mes and ret urn for furth er therapy ." Co mp lica tions include temporary ptosis, upp er lip droop , mild swelling, ecc hy rnosis, and local d iscomforl.
Botul inum toxin ca n be an excelle nt alternative or adj unctive tre atmerit to topi eal agents, che rn ic al peel , laser resurfacin g, soft tissue aug menta tion, or surger y. No major or long-t erm co mplications have been reported foll owing cosm etic botulinum toxin injections. T he maximum degree of ex pec ted impra vem ent ca n be sirn ulated by spreading apa rt the wr inkle to be tre ated with two finge rs." But becau se imp ra vem ent is only temporary , so me pati ents opt to disco ntinue botulinum toxin inje ction treatment and und ergo a permanent but more invasive procedure. How ever, these approa ches are often ine ffecti ve and can leave visible incision sears, Pat ient s who are most likely to fail botulinum toxin injecti on therapyare those who ha ve th ick , se bace ous skin, deep derrnal sca rri ng, ex trao rd ina rily dee p Iines, excess sk in laxity as aresult of ag ing, incomplete den ervatio n, and aecesscry mu scle function th at co ntributes to the wrinkling.v-'"
Cricopharyngeal spasm
Botulinum to xin can be used to correct voi ce failure foll owin g tracheoesoph ageal pun cture and dy sph agia seeondary to cricopha ry nge al spas m. Cricopha rynge al spa sm has been rep ort ed to be a cause of fa ilure of voice restoration foll owin g tra cheoesoph ageal pun cture in as many as 12% of laryngect om y pati ents." It is so metimes difficult to make thi s d iagn osis, but a barium swallow, esophageal manorn et ry , and EMG showi ng persistent spas m on sw allow can be help fuI. Injection of botulinum toxin int o the crico phary nge us ca n be used diagn ost icall y and therapeuti cally in patients who ha ve vo ice failure or dysph agia secondary to crico pha rynge al hyper acti vit y.t''-" Under 80 0 EM G guida nce , the cricoph aryn geus is injected at two or thr ee sites on each side, supe rior and lat eral to the laryngec to my stoma. Th e cr icopharyngeu s is identified by electrical act ivity at rest that dim inishes or stops when the pati ent swa llows, Th e cricoph ar yngeu s can also be inj ect ed endos co pica IIy. Blitzer et al studied six pat ient s wh o had voice failure secondary to crico pha ry ngeal spasm and found that all six benefited from botulinum toxi n inj ec tions, including tw o wh o had already undergone myotornies." We have also found ternp orary ben efits in a small number of patients (unpublished data, 1997 to present ). Do ses ave rag e 30 to 40 MU, and effects last abo ut 3 months.
Thi s technique is also useful for pat ients who have dy sphagia secondary to cric oph aryn ge al spas m as aresult o f a neurologic impa irment such as stroke, for tho se who have discoordinated swallow ing, and for tho se who have undergone a 1aryngectomy. B1itzer and Brin rep orted impravement in six of six pat ient s with 10 MU spread ov er four inj ection sites." In another study, Anne se et al co mpar ed pneumatic dil ation with botulinum toxin injection in 16 patients with ach alasia and elevated lower esophageal sphincter tone and found that the tox in was compara ble to dil ation with regard to symptom scores , eve n though dil ation led to a signif icantly lo wer sphincter pressu re.? Th ere are no published studies co mpari ng d ilati on and botul inum toxin in crico phary ngeal spas m.
T ypi cally , treatrnent effects become evide nt after a fe w day s and can last up to 5 months. No major side effects have been reported. Some pati ents prefer botulinum toxin inj ection s as an altern at ive to myotomy or dilation. Patient selection is important and clinical tri a1s are lacking, but this might become an indication fo r wh ich botulinum toxin might prove to be ver y beneficiaI.
In concl us ion, additional rese arch-incl ud ing ca reful do cumentatio n a n d the reportin g o f re sults of otolaryngologic applica tions ofbotulinum toxin-shou1d be encouraged to help answ er the remaining questions and c1arify the roles ofbotulinum toxin in otolaryngology.
